REACHing Communities (REACH) Consortium (U01) Clinical Trials Optional

Summary

The Food and Drug Administration (FDA) is forecasting a grant/cooperative agreement opportunity under the REACHing Communities (REACH) Consortium mechanism (U01), with clinical trials designated as optional. The U01 mechanism indicates a cooperative agreement where the federal sponsor retains substantial programmatic involvement. The opportunity is aimed at community-focused research efforts, likely targeting underrepresented or underserved populations in FDA-regulated research. Full details, including scope, award amounts, and eligibility, were not yet published at the time of the forecast notice.

What they want

How they evaluate

Risks & flags

• Forecasted notice only — no full FOA published; scope, eligibility, and award details are unavailable, making competitive assessment impossible at this stage.
• U01 cooperative agreement mechanism implies significant FDA programmatic involvement, which may limit bidder flexibility and favor incumbents with existing FDA relationships.